

Jialan Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/307323/publications.pdf>

Version: 2024-02-01

66
papers

1,631
citations

361413

20
h-index

315739

38
g-index

68
all docs

68
docs citations

68
times ranked

1887
citing authors

#	ARTICLE	IF	CITATIONS
1	Lactadherin binds selectively to membranes containing phosphatidyl-l-serine and increased curvature. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2004, 1667, 82-90.	2.6	172
2	Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. <i>Blood</i> , 2003, 101, 2628-2636.	1.4	163
3	Neutrophil Extracellular Traps Induce Intestinal Damage and Thrombotic Tendency in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 240-253.	1.3	102
4	Lactadherin detects early phosphatidylserine exposure on immortalized leukemia cells undergoing programmed cell death. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2006, 69A, 1193-1201.	1.5	97
5	Interactions between neutrophil extracellular traps and activated platelets enhance procoagulant activity in acute stroke patients with ICA occlusion. <i>EBioMedicine</i> , 2020, 53, 102671.	6.1	87
6	Phosphatidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 738-751.	3.4	72
7	Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role. <i>Frontiers in Immunology</i> , 2019, 10, 1809.	4.8	63
8	Neutrophil extracellular traps enhance procoagulant activity in patients with oral squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1695-1707.	2.5	58
9	Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 861703.	3.9	53
10	COVID-19 and ischemic stroke: Mechanisms of hypercoagulability (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	4.0	47
11	Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis. <i>Scientific Reports</i> , 2017, 7, 4978.	3.3	45
12	Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release. <i>PLoS ONE</i> , 2015, 10, e0142835.	2.5	44
13	Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia. <i>Blood</i> , 2017, 129, 1855-1864.	1.4	41
14	Neutrophil extracellular traps induced by activated platelets contribute to procoagulant activity in patients with colorectal cancer. <i>Thrombosis Research</i> , 2019, 180, 87-97.	1.7	40
15	Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine. <i>Blood</i> , 2015, 126, 1237-1244.	1.4	37
16	Indolic Uremic Solutes Enhance Procoagulant Activity of Red Blood Cells through Phosphatidylserine Exposure and Microparticle Release. <i>Toxins</i> , 2015, 7, 4390-4403.	3.4	37
17	Phosphatidylserine-exposing blood cells and microparticles induce procoagulant activity in non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 258, 138-143.	1.7	33
18	Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. <i>Cell Death and Disease</i> , 2018, 9, 75.	6.3	32

#	ARTICLE	IF	CITATIONS
19	Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activity in patients with pancreatic cancer. <i>Thrombosis Research</i> , 2020, 188, 5-16.	1.7	25
20	Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke. <i>Translational Stroke Research</i> , 2017, 8, 83-91.	4.2	22
21	Neutrophil extracellular traps contribute to tissue plasminogen activator resistance in acute ischemic stroke. <i>FASEB Journal</i> , 2021, 35, e21835.	0.5	22
22	Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation. <i>International Journal of Cardiology</i> , 2016, 223, 121-128.	1.7	21
23	Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients. <i>Annals of Hematology</i> , 2018, 97, 605-616.	1.8	21
24	<p>808 nm Near-Infrared Light-Excited UCNPs@mSiO<sub>2</sub>-Ce6-GPC3 Nanocomposites For Photodynamic Therapy In Liver Cancer<p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 10009-10021.	6.7	21
25	Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis. <i>Liver International</i> , 2016, 36, 1800-1810.	3.9	19
26	Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 627-634.	3.4	17
27	Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101697.	1.5	17
28	Intravascular cells and circulating microparticles induce procoagulant activity via phosphatidylserine exposure in heart failure. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 187-194.	2.1	16
29	Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 747-759.	0.7	15
30	Phagocytosis by endothelial cells inhibits procoagulant activity of platelets of essential thrombocythemia in vitro. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 222-233.	3.8	15
31	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	3.5	15
32	Persistent Lung Injury and Prothrombotic State in Long COVID. <i>Frontiers in Immunology</i> , 2022, 13, 862522.	4.8	15
33	Procoagulant Activity of Blood and Endothelial Cells via Phosphatidylserine Exposure and Microparticle Delivery in Patients with Diabetic Retinopathy. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 2411-2420.	1.6	13
34	The Exposure of Phosphatidylserine Influences Procoagulant Activity in Retinal Vein Occlusion by Microparticles, Blood Cells, and Endothelium. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-10.	4.0	12
35	Phosphatidylserine-exposing tumor-derived microparticles exacerbate coagulation and cancer cell transendothelial migration in triple-negative breast cancer. <i>Theranostics</i> , 2021, 11, 6445-6460.	10.0	12
36	Hyperuricemia enhances procoagulant activity of vascular endothelial cells through TMEM16F regulated phosphatidylserine exposure and microparticle release. <i>FASEB Journal</i> , 2021, 35, e21808.	0.5	12

#	ARTICLE	IF	CITATIONS
37	Neutrophil Extracellular Traps Exacerbate Inflammatory Responses and Thrombotic Tendency in Both a Murine Colitis Model and Patients with Inflammatory Bowel Disease. <i>Blood</i> , 2017, 130, 994-994.	1.4	11
38	Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. <i>Journal of Gastroenterology and Hepatology Research</i> , 2017, 6, 2286-2295.	0.2	11
39	Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia. <i>Frontiers in Immunology</i> , 2022, 13, 841445.	4.8	11
40	Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation. <i>Molecular Medicine Reports</i> , 2017, 16, 8579-8588.	2.4	10
41	Procoagulant activity induced by transcatheter closure of atrial septal defects is associated with exposure of phosphatidylserine on microparticles, platelets and red blood cells. <i>Thrombosis Research</i> , 2015, 136, 354-360.	1.7	8
42	Endothelial damage and a thin intercellular fibrin network promote haemorrhage in acute promyelocytic leukaemia. <i>EBioMedicine</i> , 2020, 60, 102992.	6.1	8
43	CD44-fibrinogen binding promotes bleeding in acute promyelocytic leukemia by in situ fibrin(ogen) deposition. <i>Blood Advances</i> , 2022, 6, 4617-4633.	5.2	6
44	Neutrophil extracellular traps enhance procoagulant activity and thrombotic tendency in patients with obstructive jaundice. <i>Liver International</i> , 2021, 41, 333-347.	3.9	5
45	Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 784505.	3.7	5
46	Phosphatidylserine-Mediated Platelet Clearance By Endothelium Decreases Platelet Aggregates and Procoagulant Activity in Sepsis. <i>Blood</i> , 2016, 128, 2538-2538.	1.4	4
47	TMEM16F mediated phosphatidylserine exposure and microparticle release on erythrocyte contribute to hypercoagulable state in hyperuricemia. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 96, 102666.	1.4	4
48	The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 792335.	3.7	3
49	Microvesicles, blood cells and endothelial cells mediate phosphatidylserine-related prothrombotic state in patients with periodontitis. <i>Journal of Periodontology</i> , 2021, . .	3.4	2
50	Elevated APE1 Mediates Dysregulation of Homologous Recombination in Myeloma: Mechanisms and Translational Significance. <i>Blood</i> , 2014, 124, 2074-2074.	1.4	2
51	Regulated Phosphatidylserine Exposure on Platelets Mediates Fibrin Formation in Hemostasis and Thrombosis.. <i>Blood</i> , 2005, 106, 1645-1645.	1.4	1
52	Dysregulation of SHFM1, a Novel Target for Prevention of Genomic Instability in Myeloma, Is Associated with Epigenetic Changes at Specific CpG Sites. <i>Blood</i> , 2014, 124, 862-862.	1.4	1
53	Daunorubicin Induces Procoagulant Activity of Cultured Endothelial Cells through Phosphatidylserine Exposure and Microparticles Release. <i>Blood</i> , 2010, 116, 5185-5185.	1.4	1
54	Lactadherin C2 Domain Exhibits Ptd-L-Ser Specificity and Anticoagulant Properties Distinct From Homologous Factor VIII C2 Domain and Full-Length Lactadherin. <i>Blood</i> , 2012, 120, 1105-1105.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective. <i>Platelets</i> , 2022, 33, 955-963.	2.3	1
56	Reversible Exposure of Phosphatidylserine on Thrombin-Stimulated Platelets Detected by Binding of Lactadherin.. <i>Blood</i> , 2004, 104, 3537-3537.	1.4	0
57	Procoagulant Function and Phosphatidylserine Distribution on Immortalized Acute Promyelocytic Leukemia Cells.. <i>Blood</i> , 2007, 110, 2155-2155.	1.4	0
58	Lactadherin as a Probe for Phosphatidylserine Exposure and as An Anticoagulant for the Procoagulant Activity in the Study of Stored Platelets.. <i>Blood</i> , 2009, 114, 3150-3150.	1.4	0
59	Neutrophils Clearance by Endothelial Cells Regulates Homeostasis and Coagulation.. <i>Blood</i> , 2010, 116, 3782-3782.	1.4	0
60	Erythrocytes and Platelets May Contribute to Hypercoagulability In Nephrotic Syndrome Through Enhanced Phosphatidylserine Exposure and Microparticles Release. <i>Blood</i> , 2011, 118, 36-36.	1.4	0
61	Putative Phospholipid "scramblase" of Scott Syndrome, TMEM16F/Ano6, Mediates Phosphatidylserine Exposure On Filopodia and Cell Margins of Viable Endothelial Cells.. <i>Blood</i> , 2012, 120, 2180-2180.	1.4	0
62	Thrombin-Stimulated Platelets Have Functional Binding Sites For Factor VIIIa That Are Distinct From Phosphatidylserine. <i>Blood</i> , 2013, 122, 3582-3582.	1.4	0
63	Extended Storage of Platelets in a Novel Organ Preservation Solution, Somah. <i>Blood</i> , 2014, 124, 5110-5110.	1.4	0
64	Novel Additive Solution "Aayusol" Significantly Preserves Platelets in Lesion-Free State during Extended Storage. <i>Blood</i> , 2015, 126, 3558-3558.	1.4	0
65	Neutrophil Extracellular Traps Accelerate Cholestatic Liver Injury through Bile Acids in Bile Duct Ligation Mice. <i>Blood</i> , 2016, 128, 3678-3678.	1.4	0
66	Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis. <i>Blood</i> , 2020, 136, 38-38.	1.4	0